Equity in bariatric surgery use: a cohort study
Surgery for Obesity and Related Diseases · 2024
DOI: 10.1016/j.soard.2023.12.017 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Surgery for Obesity and Related Diseases, 2024. Verfasst von Victoria Gershuni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Victoria.Gershuni@pen…. Hauptthemen laut MEDLINE: Bariatric Surgery, Health Services Accessibility. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Institutes of Health, International Business Machines Corporation, Intuitive Surgical.
Abstract (Originalsprache)
BACKGROUND: Metabolic and bariatric surgery (MBS) is the most effective and durable treatment for obesity; however, access to MBS is not equitable. OBJECTIVE: To determine the rate of MBS among eligible adults with obesity by demographics, health characteristics, and geography to better define populations that would benefit from resources to reduce barriers to access for this treatment. SETTING: Adults with obesity were identified in the US employer-based retrospective claims database (Merative™). METHODS: Rates of MBS were examined across demographics (age, sex, region, year, health plan type) health characteristics (obesity-related comorbidities, healthcare costs, inpatient admissions), and by state. Given differences in coverage requirements, rates are examined for 2 populations: Class 2 (BMI 35-39.9 kg/m2) and Class 3 (BMI 40+ kg/m2) obesity. RESULTS: Of the 777,565 eligible adults, 49,371 (6.4%) had MBS; 3.2% of those with Class 2 and 8.3% of those with Class 3 obesity had MBS. MBS rates varied substantially by demographic and health characteristics, ranging from 1% to 14%, and from 2% to 41% among those with Class 2 and Class 3 obesity, respectively. Geographically, rates ranged from 0% (Hawaii) to 7.4% (New Mexico) for those with Class 2 Obesity and from 4.2% (Hawaii) to 15.3% (Mississippi) among those with Class 3 Obesity. CONCLUSIONS: Use of MBS among eligible adults with obesity varies substantially across characteristics, indicating inequity in access to this treatment. To ensure greater access to the most effective treatment for obesity, policies should be implemented to reduce or eliminate barriers to care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Victoria.Gershuni@pennmedicine.upenn.edu.
- Global Health Economics and Outcomes Research, Intuitive Surgical, Sunnyvale, California; Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
- Global Health Economics and Outcomes Research, Intuitive Surgical, Sunnyvale, California.
- Global Health Economics and Outcomes Research, Intuitive Surgical, Sunnyvale, California; DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
- Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Förderung
- National Institutes of Health
- International Business Machines Corporation
- Intuitive Surgical
- National Center for Advancing Translational Sciences
Zitieren
APA
Gershuni, V., Wall-Wieler, E., Liu, Y., Zheng, F., & Altieri, M. S. (2024). Equity in bariatric surgery use: a cohort study. Surgery for Obesity and Related Diseases. https://doi.org/10.1016/j.soard.2023.12.017
Vancouver
Gershuni V, Wall-Wieler E, Liu Y, Zheng F, Altieri MS. Equity in bariatric surgery use: a cohort study. Surgery for Obesity and Related Diseases. 2024. doi:10.1016/j.soard.2023.12.017
BibTeX
@article{Gershuni2024,
author = {Gershuni, Victoria and Wall-Wieler, Elizabeth and Liu, Yuki and Zheng, Feibi and Altieri, Maria S},
title = {Equity in bariatric surgery use: a cohort study},
journal = {Surgery for Obesity and Related Diseases},
year = {2024},
doi = {10.1016/j.soard.2023.12.017}
}
EUVIMED